Supplementary Figure S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25607436.v1

2024-01-01

Abstract:Supplementary Figure S1 shows that CoCl2 CM enhances breast cancer glycolysis.

What problem does this paper attempt to address?

Supplementary Figure S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25731645

2024-01-01

Abstract:Supplementary Figure S2 shows that BCSC CM enhances the aerobic glycolysis not oxidative phosphorylation.
Supplementary Figure S4 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25731639

2024-01-01

Abstract:Supplementary Figure S4 shows that MIF secreted by BCSCs to enhance the glycolysis of breast cancer cells.
Supplementary Figure S5 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25731636.v1

2024-01-01

Abstract:Supplementary Figure S5 shows that MIF promotes cancer cell proliferation, migration and invasion.
Supplementary Figure S6 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25731633.v1

2024-01-01

Abstract:Supplementary Figure S6 shows that BCSCs regulate cancer cell metabolic reprogramming through ALDOC.
Supplementary Figure S8 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25607415.v1

2024-01-01

Abstract:Supplementary Figure S8 shows that Targeting MIF enhances cancer cell sensitivity to immune cell killing.
Supplementary Figure S3 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25603300

2024-01-01

Abstract:Supplementary Figure S3 shows that MIF is identified as a key cytokine secreted by BCSC.
Supplementary Figure S7 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25731630

2024-01-01

Abstract:Supplementary Figure S7 shows that MIF is associated with immunosuppressive Tumor microenvironment.
Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.can-23-2390

IF: 11.2

2024-02-11

Cancer Research

Abstract:Reprogramming of energy metabolism exerts pivotal functions in cancer progression and immune surveillance. Identification of the mechanisms mediating metabolic changes in cancer may lead to improved strategies to suppress tumor growth and stimulate anti-tumor immunity. Here, it was observed that the secretomes of hypoxic breast cancer cells and breast cancer stem cells (BCSCs) induced reprogramming of metabolic pathways, particularly glycolysis, in normoxic breast cancer cells. Screening of the BCSC secretome identified MIF as a pivotal factor potentiating glycolysis. Mechanistically, MIF increased c-MYC-mediated transcriptional upregulation of the glycolytic enzyme aldolase C by activating WNT/β-CATENIN signaling. Targeting MIF attenuated glycolysis and impaired xenograft growth and metastasis. MIF depletion in breast cancer cells also augmented intratumoral cytolytic CD8+ T cells and pro-inflammatory macrophages while decreasing Tregs and tumor-associated neutrophils in the tumor microenvironment. Consequently, targeting MIF improved the therapeutic efficacy of immune checkpoint blockade (ICB) in triple-negative breast cancer. Collectively, this study proposes MIF as an attractive therapeutic target to circumvent metabolic reprogramming and immunosuppression in breast cancer.

oncology
Data from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.can-23-2390

IF: 11.2

2024-01-01

Cancer Research

Abstract:AbstractReprogramming of energy metabolism exerts pivotal functions in cancer progression and immune surveillance. Identification of the mechanisms mediating metabolic changes in cancer may lead to improved strategies to suppress tumor growth and stimulate antitumor immunity. Here, it was observed that the secretomes of hypoxic breast cancer cells and breast cancer stem cells (BCSC) induced reprogramming of metabolic pathways, particularly glycolysis, in normoxic breast cancer cells. Screening of the BCSC secretome identified MIF as a pivotal factor potentiating glycolysis. Mechanistically, MIF increased c-MYC–mediated transcriptional upregulation of the glycolytic enzyme aldolase C by activating WNT/β-catenin signaling. Targeting MIF attenuated glycolysis and impaired xenograft growth and metastasis. MIF depletion in breast cancer cells also augmented intratumoral cytolytic CD8+ T cells and proinflammatory macrophages while decreasing regulatory T cells and tumor-associated neutrophils in the tumor microenvironment. Consequently, targeting MIF improved the therapeutic efficacy of immune checkpoint blockade in triple-negative breast cancer. Collectively, this study proposes MIF as an attractive therapeutic target to circumvent metabolic reprogramming and immunosuppression in breast cancer.Significance:MIF secreted by breast cancer stem cells induces metabolic reprogramming in bulk tumor cells and engenders an immunosuppressive microenvironment, identifying MIF targeting as a strategy to improve immunotherapy efficacy in breast cancer.
Lactate Promotes Metastasis of Normoxic Colorectal Cancer Stem Cells Through PGC-1α-mediated Oxidative Phosphorylation

Shuang Liu,Hui Zhao,Yibing Hu,Chang Yan,Yulong Mi,Xiaolan Li,Deding Tao,Jichao Qin

DOI: https://doi.org/10.1038/s41419-022-05111-1

2022-01-01

Cell Death and Disease

Abstract:Uneven oxygen supply in solid tumors leads to hypoxic and normoxic regions. Hypoxic cells exhibit increased secretion of lactate, which creates an acidic tumor microenvironment (TME). This acidic TME is positively associated with tumor metastasis. Despite the increased metastatic capacity of hypoxic cells, they are located relatively further away from the blood vessels and have limited access to the circulatory system. Studies have shown that cancer stem cells (CSCs) are enriched for tumor metastasis-initiating cells and generally undergo aerobic respiration, which could be enhanced by lactate. We therefore hypothesized that TME-derived lactate may promote the metastasis of normoxic CSCs. In the present study, the abundance of hypoxic and normoxic CSCs was analyzed in primary CRC tumors. It was found that the proportion of normoxic CSCs was positively associated with tumor stage. Using two human CRC cell lines, LoVo and SW480, and a patient-derived xenograft (XhCRC), it was found that treatment with lactate promoted normoxic CSC metastasis. Metabolism analysis indicated that, upon treatment with lactate, oxidative phosphorylation (OXPHOS) activity in normoxic CSCs was enhanced, whereas hypoxic CSCs were rarely altered. At the molecular level, the expression of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), a master regulator of lactate oxidation, was found to be elevated in normoxic CSCs. Furthermore, PGC-1α knockdown markedly reduced the metastatic potential of normoxic CSCs. Notably, both the PGC-1α-mediated OXPHOS activity and metastatic potential were impaired when hypoxia-inducible factor-1α (HIF-1α) was activated in normoxic CSCs. Together, these findings provide a therapeutic strategy against tumor metastasis through the targeting of PGC-1α and, thus, the suppression of lactate-feeding OXPHOS in normoxic CSCs may improve the therapeutic benefit of patients with cancer, particularly CRC.
Table S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Linlin Yan,Mingming Wu,Tianyu Wang,Hui Yuan,Xiao Zhang,Huafeng Zhang,Tao Li,Vijay Pandey,Xinghua Han,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.25731624

2024-01-01

Abstract:Table S1 shows the sequences of sgRNAs, shRNAs and primers for cloning and qRT-PCR analysis.
Cancer Stem Cell Regulated Phenotypic Plasticity Protects Metastasized Cancer Cells from Ferroptosis

Mingming Wu,Xiao Zhang,Weijie Zhang,Yi Shiou Chiou,Wenchang Qian,Xiangtian Liu,Min Zhang,Hong Yan,Shilan Li,Tao Li,Xinghua Han,Pengxu Qian,Suling Liu,Yueyin Pan,Peter E. Lobie,Tao Zhu

DOI: https://doi.org/10.1038/s41467-022-29018-9

IF: 16.6

2022-01-01

Nature Communications

Abstract:Cancer cells display phenotypic equilibrium between the stem-like and differentiated states during neoplastic homeostasis. The functional and mechanistic implications of this subpopulation plasticity remain largely unknown. Herein, it is demonstrated that the breast cancer stem cell (BCSC) secretome autonomously compresses the stem cell population. Co-implantation with BCSCs decreases the tumor-initiating capacity yet increases metastasis of accompanying cancer cells, wherein DKK1 is identified as a pivotal factor secreted by BCSCs for such functions. DKK1-promotes differentiation is indispensable for disseminated tumor cell metastatic outgrowth. In contrast, DKK1 inhibitors substantially relieve the metastatic burden by restraining metastatic cells in the dormant state. DKK1 increases the expression of SLC7A11 to protect metastasizing cancer cells from lipid peroxidation and ferroptosis. Combined treatment with a ferroptosis inducer and a DKK1 inhibitor exhibits synergistic effects in diminishing metastasis. Hence, this study deciphers the contribution of CSC-regulated phenotypic plasticity in metastatic colonization and provides therapeutic approaches to limit metastatic outgrowth. The contribution of breast cancer stem cells (BCSCs) to metastasis needs further elucidation. Here, the authors show that BCSCs secrete DKK1 to protect metastasizing cancer cells from ferroptosis via upregulation of SLC7A11, and further show that the combination of a ferroptosis inducer with a DKK1 inhibitor reduces metastasis.
Loss of MiR-192-5p Initiates a Hyperglycolysis and Stemness Positive Feedback in Hepatocellular Carcinoma.

Yuanzhuo Gu,Fubo Ji,Niya Liu,Yongzhi Zhao,Xiyang Wei,Shiyuan Hu,Wei Jia,Xin Wei Wang,Anuradha Budhu,Juling Ji,Bin Zhao,Stephanie Roessler,Xin Zheng,Junfang Ji

DOI: https://doi.org/10.1186/s13046-020-01785-7

2020-01-01

Abstract:Background Emerging studies revealed that cancer stem cells (CSCs) possessed peculiar metabolic properties, which however remained largely unknown in hepatocellular carcinoma (HCC). Genetic silencing of liver-abundant miR-192-5p was a key feature for multiple groups of CSC-positive HCCs. We thus aimed to investigate essential metabolic features of hepatic CSCs via using HCCs with miR-192-5p silencing as a model. Methods Datasets from two independent HCC cohorts were used. Data integration analyses of miR-192-5p with metabolome and mRNA transcriptome data in HCC Cohort 1 were performed to investigate miR-192-5p related metabolic features, which was further validated in Cohort 2. Cellular and molecular assays were performed to examine whether and how miR-192-5p regulated the identified metabolic features. Co-culture systems consisting of HCC cells and LX2 (human hepatic stellate cell line) or THP1 (human monocyte cell line) were established to explore effects of the identified metabolic properties on stemness features of HCC cells via interacting with co-cultured non-tumor cells. Results High levels of glycolysis-related metabolites and genes were present in HCCs with low miR-192-5p and CSC-positive HCCs in two independent HCC cohorts. miR-192-5p knockout cells displayed CSC features and miR-192-5p loss led to an enhanced glycolytic phenotype via upregulating three bona fide targets, GLUT1 and PFKFB3 (two glycolytic enzymes) and c-Myc (regulating glycolytic genes’ expression). Meanwhile, c-Myc suppressed miR-192-5p transcription, ensuring a low-miR-192-5p/high-c-Myc loop to maintain hyperglycolysis. Moreover, over-produced lactic acid from hyperglycolytic HCC cells stimulated the ERK phosphorylation of co-cultured LX2 and THP1 non-tumor cells partially via NDRG3 and MCT1, which in turn promoted cell malignancy and stemness of HCC cells. Consistently, HCC patients with low level of miR-192-5p in their tumor tissues and high level of NDRG3 or MCT1 in their non-tumor tissues had the shortest overall survival. Conclusions In CSC-positive HCCs, miR-192-5p loss enhanced glycolysis and over produced lactate might further increase HCC malignant features via interacting with environmental non-tumor cells.
Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497787

2023-01-01

Abstract:PDF file - 63K, Figure S1: Expression of RON and MET by breast cancer MCF-7, T-47D and ZR-75-1 cells.
TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer

Megan E Roche,Ying-Hui Ko,Marina Domingo-Vidal,Zhao Lin,Diana Whitaker-Menezes,Ruth C Birbe,Madalina Tuluc,Balázs Győrffy,Jaime Caro,Nancy J Philp,Ramon Bartrons,Ubaldo Martinez-Outschoorn

DOI: https://doi.org/10.1002/ijc.34660

2023-11-01

Abstract:Breast cancer is composed of metabolically coupled cellular compartments with upregulation of TP53 Induced Glycolysis and Apoptosis Regulator (TIGAR) in carcinoma cells and loss of caveolin 1 (CAV1) with upregulation of monocarboxylate transporter 4 (MCT4) in fibroblasts. The mechanisms that drive metabolic coupling are poorly characterized. The effects of TIGAR on fibroblast CAV1 and MCT4 expression and breast cancer aggressiveness was studied using coculture and conditioned media systems and in-vivo. Also, the role of cytokines in promoting tumor metabolic coupling via MCT4 on cancer aggressiveness was studied. TIGAR downregulation in breast carcinoma cells reduces tumor growth. TIGAR overexpression in carcinoma cells drives MCT4 expression and NFkB activation in fibroblasts. IL6 and TGFB drive TIGAR upregulation in carcinoma cells, reduce CAV1 and increase MCT4 expression in fibroblasts. Tumor growth is abrogated in the presence of MCT4 knockout fibroblasts and environment. We discovered coregulation of c-MYC and TIGAR in carcinoma cells driven by lactate. Metabolic coupling primes the tumor microenvironment allowing for production, uptake and utilization of lactate. In sum, aggressive breast cancer is dependent on metabolic coupling.
Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Zhou Jiang,Jennifer L. Hsu,Yintao Li,Gabriel N. Hortobagyi,Mien-Chie Hung

DOI: https://doi.org/10.3389/fonc.2020.01197

IF: 4.7

2020-07-22

Frontiers in Oncology

Abstract:Immune checkpoint inhibitors (ICIs) targeting immune checkpoint proteins, such as CTLA-4 and PD-1/PD-L1, have demonstrated remarkable and durable clinical responses in various cancer types. However, a considerable number of patients receiving ICIs eventually experience a relapse due to diverse resistance mechanisms. As a result, there have been increasing research efforts to elucidate the molecular mechanisms behind resistance to ICIs and improve patient outcomes. There is growing evidence that the dysregulated metabolic activity of tumor cells generates an immunosuppressive tumor microenvironment (TME) that orchestrates an impaired anti-tumor immune response. Notably, the immunosuppressive TME is characterized by nutrient shortage, hypoxia, an acidic extracellular milieu, and abundant immunosuppressive molecules. A detailed understanding of the TME remains a major challenge in mounting a more effective anti-tumor immune response. Herein, we discuss how tumor cells reprogram metabolism to modulate a pro-tumor TME, driving disease progression and immune evasion; in particular, we highlight potential approaches to target metabolic vulnerabilities in the context of anti-tumor immunotherapy.

oncology
Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis

Chong Chen,Lipeng Bai,Fengqi Cao,Shengnan Wang,Huiwen He,Mingcheng Song,Huilin Chen,Yan Liu,Jian Guo,Qin Si,Yundi Pan,Ruizhe Zhu,Tsung-Hsien Chuang,Rong Xiang,Yunping Luo

DOI: https://doi.org/10.1038/s41388-019-0735-4

IF: 8.756

2019-02-11

Oncogene

Abstract:The altered metabolism and acidic microenvironment plays an important role in promoting tumor malignant characteristics. A small population of cancer stem cells (CSCs) were considered as a therapy target to reserve tumor relapse, resistance, and metastasis. However, the molecular mechanism that regulates CSCs metabolism remains poorly understood. In this study, we demonstrate a fundamental role of stemness gene LIN28B in maintaining CSCs glycolysis metabolism. Using LIN28B-expressing cancer cell lines, we found that the rate of extracellular acidification, glucose uptake, and lactate secretion are all suppressed by LIN28B knockdown in vitro and in vivo. Importantly, metabolic analyses reveal that CSCs have enhanced aerobic glycolysis metabolic characteristics and the glycolytic product lactate further promotes cancer associated stemness properties. LIN28B silencing suppresses MYC expression that further increases miR-34a-5p level. Furthermore, the glycolysis metabolism of human breast cancer cell line MDA-MB-231 is suppressed by either MYC siRNA or miR-34a-5p mimic. Clinically, high MYC and low miR-34a-5p level are correlated with high LIN28B expression and poor prognosis in human breast cancer patients. Notably, blocking LIN28B/MYC/miR-34a-5p signaling pathway by LIN28B-specific inhibitor causes dramatic inhibition of tumor growth and metastasis in immunodeficient orthotopic mouse models of human breast cancer cell MDA-MB-231. Taken together, our findings offer a preclinical investigation of targeting LIN28B to suppress CSCs glycolysis metabolism and tumor progression that may improve the therapeutic benefit for cancer patients.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Supplementary Figures 15 from Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks

Suling Liu,Christophe Ginestier,Sing J. Ou,Shawn G. Clouthier,Shivani H. Patel,Florence Monville,Hasan Korkaya,Amber Heath,Julie Dutcher,Celina G. Kleer,Younghun Jung,Gabriela Dontu,Russell Taichman,Max S. Wicha

DOI: https://doi.org/10.1158/0008-5472.22386182

2023-01-01

Abstract:Supplementary Figures 15 from Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks
Supplementary Figure S15 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer

Hao Chen,Gregory M. Cresswell,Sarah Libring,Mitchell G. Ayers,Jinmin Miao,Zhong-Yin Zhang,Luis Solorio,Timothy L. Ratliff,Michael K. Wendt

DOI: https://doi.org/10.1158/2767-9764.22545144.v1

2023-01-01

Abstract:Growth factors and 3D culture environment induce PD-L1 in MBC cells.
Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming

Ting Yu,Zhaoyun Liu,Qingxu Tao,Xin Xu,Xinyang Li,Yang Li,Minxin Chen,Rufei Liu,Dawei Chen,Meng Wu,Jinming Yu

DOI: https://doi.org/10.1016/j.canlet.2024.216824

2024-05-01

Abstract:Immunotherapy, especially immune checkpoint inhibitors, has revolutionized clinical practice within the last decade. However, primary and secondary resistance to immunotherapy is common in patients with diverse types of cancer. It is well-acknowledged that tumor cells can facilitate the formation of immunosuppressive microenvironments via metabolism reprogramming, and lactic acid, the metabolite of glycolysis, is a significant contributor. SLC16A3 (also named as MCT4) is a transporter mediating lactic acid efflux. In this study, we investigated the role of glycolysis in immunotherapy resistance and aimed to improve the immunotherapy effects via Slc16a3 inhibition. Bioinformatical analysis revealed that the expression of glycolysis-related genes correlated with less CD8+ T cell infiltration and increased myeloid-derived suppressor cells (MDSC) enrichment. We found that high glycolytic activity in tumor cells adversely affected the antitumor immune responses and efficacy of immunotherapy and radiotherapy. As the transporter of lactic acid, SLC16A3 is highly expressed in glycolytic B16-F10 (RRID: CVCL_0159) cells, as well as human non-small cell lung carcinoma. We validated that Slc16a3 expression in tumor cells negatively correlated with anti-PD-1 efficiency. Overexpression of Slc16a3 in tumor cells promoted lactic acid production and efflux, and reduced tumor response to anti-PD-1 inhibitors by inhibiting CD8+ T cell function. Genetic and pharmacological inhibition of Slc16a3 dramatically reduced the glycolytic activity and lactic acid production in tumor cells, and ameliorated the immunosuppressive tumor microenvironments (TMEs), leading to boosted antitumor effects via anti-PD-1 blockade. Our study therefore demonstrates that tumor cell-intrinsic SLC16A3 may be a potential target to reverse tumor resistance to immunotherapy.

Supplementary Figure S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S2 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S4 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S5 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S6 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S8 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S3 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S7 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming that Drives Immune Evasion

Data from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Lactate Promotes Metastasis of Normoxic Colorectal Cancer Stem Cells Through PGC-1α-mediated Oxidative Phosphorylation

Table S1 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Cancer Stem Cell Regulated Phenotypic Plasticity Protects Metastasized Cancer Cells from Ferroptosis

Loss of MiR-192-5p Initiates a Hyperglycolysis and Stemness Positive Feedback in Hepatocellular Carcinoma.

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis

Supplementary Figures 15 from Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks

Supplementary Figure S15 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer

Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming